1van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Antibodies to cyclic citrullinated peptide predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum, 2004,50: 709-715.
2Schellekens G, Visser H, de Jong B, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum, 2000,43: 155-163.
3Kroot EJ, de Jong BA, van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum, 2000, 43: 1831-1835.
4Bizzaro N, Mazzanti G, Tonutti E, et al. Diagnostic accuracy of the anti-citrulline antibodies assay for rheumatoid arthritis. Clin Chem, 2001,47:1089-1093.
5Suzuki K, Sawada T, Murakami A, et al. High diagnostic performance of ELISA detection of antibodies to citrullinate antigens in rheumatoid arthritis. Scand J Rheum, 2003,32: 197-204.
6Palosuo T, Tilvis R, Strandberg T, et al. Filaggrin related antibodies among the aged. Ann Rheum Dis, 2003, 62:261-263.
7Lopez-Hoyos M, Ruiz de Alegria C, Blanco R, et al. Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica. Rheumatology (Oxford), 2004,43: 655-657.
8Mediwake R, Isenberg DA, Schellekens GA, et al. Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rhem Dis, 2001, 60: 67-68.
9Olivieri I, Palazzi C, Padula A. Hepatitis C virus and arthritis. Rheum Dis Clin North Am, 2003,29: 111-122.
10Toubi E, Zuckerman E, Kessel A, et al. IgA rheumatoid factor in patients with chronic HCV infection: prevalence and clinical correlations. Clin Exp Rheumatol, 2003, 21: 524.
